Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.48 |
| ▸ | CES1 | P23141 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263465 | 1.00 | CES2 (0.48) | CES2CES1EPHX2TBXAS1NAAA | |
| SCHEMBL4473785 | 0.74 | EP300 (0.42) | EPHX2EP300SOAT1 | |
| SCHEMBL4473788 | 0.74 | EP300 (0.42) | EPHX2EP300SOAT1 | |
| SCHEMBL7451708 | 0.74 | EP300 (0.64) | CES2CES1EPHX2TBXAS1NAAA | |
| Ammonia Solution, Strong SCHEMBL28224094 | 0.74 | EP300 (0.59) | CES2CES1EPHX2TBXAS1NAAA | |
| SCHEMBL11560694 | 0.74 | EP300 (0.64) | CES2CES1EPHX2TBXAS1NAAA | |
| Bicarbonate SCHEMBL7690247 | 0.72 | TBXAS1 (0.52) | CES2CES1TBXAS1 | |
| SCHEMBL597783 | 0.71 | EP300 (0.50) | CES2CES1EPHX2TBXAS1NAAA | |
| SCHEMBL597781 | 0.71 | EP300 (0.50) | CES2CES1EPHX2TBXAS1NAAA | |
| SCHEMBL11778913 | 0.71 | CES2 (0.41) | CES2CES1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030114538-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-06-19 | — | — | US | disclosed |
| US-6548553-B2 | Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-15 | — | — | US | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | CES2 1024/4885CES1 998/4885EPHX2 1265/4885 |
| US-20030114538-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | CES2 1576/4885CES1 1179/4885EPHX2 4095/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | CES2 1576/4885CES1 1179/4885EPHX2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.